Contract research firm IQVIA Holdings beat Wall Street estimates for fourth-quarter profit and revenue on Thursday, helped by the demand for its healthcare data and analytics services.
The 2025 forecast reflects a revenue hit of about 18% to 20% to the company's legacy portfolio from the near-term effects of generics on cancer drugs Revlimid, Pomalyst, Sprycel and Apraxane. The ...
Semiconductor testing company FormFactor (NASDAQ:FORM) in Q4 CY2024, with sales up 12.7% year on year to $189.5 million. On ...
CEO Anders Opedal announced plans to deliver more than 10% growth in oil and gas production from 2024 to 2027, supported by portfolio optimization and high-value transactions. He stated that Equinor ...
French oil major TotalEnergies beat expectations for fourth-quarter earnings on Wednesday as higher trading profits in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results